At the 36th ECNP Congress in Barcelona Spain October 6-10, 2023, Professor Bo Söderpalm, Addiction Biology Unit, Institute of Neuroscience and Physiology, University of Gothenburg, Sweden, presented the promising results from the Phase 2 trial in Sweden with patients suffering from Alcohol Use Disorder (AUD). The results aroused great interest among the congress participants. The study, announced this spring, has evaluated the efficacy, safety, and tolerability of the combination of varenicline and bupropion vs. placebo for patients with moderate to severe AUD.

Read More